Formulary assessment – indapamide 1.5mg modified release
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Monthly Formulary Amendments – March 2022
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, RMOC Guidance, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Monthly Horizon Scanning Report – March 2022
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Insulin aspart Sanofi (Trurapi): Biosimilar Insulin Aspart
Overview
Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.
Insulin aspart Sanofi (Trurapi®▼) is the first biosimilar of insulin aspart (NovoRapid®). It is licensed for the treatment of diabetes mellitus in adults, adolescents, and children aged >1 year. This publication reviews its efficacy and safety, and the limitations of the evidence.
Wound Management & Other Dressings
Overview
This report looks at prescribing trends in primary care for Wound Management & Other Dressings at CCG and STP level with particular focus on antibiotic dressings.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Annually
Data Period
April 2018 to March 2021
This report has been discontinued. If you would like an updated version of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Oral Nutrition
Overview
This report looks at prescribing trends in primary care for Oral Nutrition at CCG and STP level with particular focus on Enteral Nutrition, Foods for Special Diets and Infant Feeds.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Annually
Data Period
April 2018 to March 2021
This report has been discontinued. If you would like an updated version of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Gastro-intestinal System
Overview
This report looks at prescribing trends in primary care for for the Gastro-intestinal system at CCG and STP level with particular focus on Dyspepsia, Antisecretory drugs, Acute Diarrhoea, Chronic Bowel Disorders and Laxatives.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Bi-annually
Data Period
April 2018 to March 2021
This report has been discontinued. If you would like an updated version of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Drugs for Genito-urinary disorders
Overview
This report looks at prescribing trends in primary care for Drugs for Genito-urinary disorders at CCG and STP level with particular focus on Drugs for Urinary Retention, Drugs for Urinary Frequency, Enuresis and Incontinence and Drugs for Erectile Dysfunction.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Bi-annually
Data Period
April 2018 to March 2021
This report has been discontinued. If you would like an updated version of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Monthly Horizon Scanning Report – March 2021
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.